Viking Therapeutics Poised for Growth in Weight-Loss Drug Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 13 hours ago
0mins
Should l Buy VKTX?
Source: NASDAQ.COM
- Market Potential: According to Mordor Intelligence, the anti-obesity drug market is projected to grow from $26 billion last year to over $130 billion by 2031, indicating strong growth potential, with Viking Therapeutics well-positioned in this space.
- Clinical Trial Success: Viking Therapeutics' VK2735 achieved an average weight loss of up to 14.7% in just 13 weeks, outperforming other options on the market, showcasing its competitive edge in the weight-loss drug sector and potentially attracting more users.
- Analyst Optimism: Wall Street's consensus price target for Viking Therapeutics stands at $93.59, over 170% above its current price, reflecting analysts' strong optimism regarding upcoming clinical trial data and suggesting potential FDA approval.
- Differentiation Advantage: VK2735, as a dual agonist incorporating both GLP-1 and GIP therapies, offers a competitive edge with its tolerability and efficacy, which may help it stand out in a crowded market despite similarities in underlying mechanisms with other drugs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.800
Low
70.00
Averages
97.00
High
125.00
Current: 32.800
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics' Bullish Outlook with Target Price Raised Significantly
- Target Price Surge: Analysts project Viking Therapeutics' stock to reach $93.59 within the next 12 months, representing a more than 170% increase from its current price, indicating strong market confidence in its weight-loss drug VK2735.
- Clinical Trial Success: VK2735 achieved an average weight loss of up to 14.7% in just 13 weeks, outperforming other market options, with most users able to adhere to the treatment regimen, providing a significant competitive edge in the crowded weight-loss drug market.
- Massive Market Potential: The anti-obesity drug market is expected to grow from $26 billion last year to over $130 billion by 2031, positioning Viking Therapeutics to capture a share of this rapidly expanding market with its unique dual agonist VK2735.
- Analyst Optimism: Despite inherent risks, analysts remain bullish on Viking Therapeutics, anticipating that upcoming Phase 3 trial data will lead to FDA approval by no later than 2029, suggesting a strong buy sentiment among the majority of analysts covering the stock.
See More
Viking Therapeutics Poised for Growth in Weight-Loss Drug Market
- Market Potential: According to Mordor Intelligence, the anti-obesity drug market is projected to grow from $26 billion last year to over $130 billion by 2031, indicating strong growth potential, with Viking Therapeutics well-positioned in this space.
- Clinical Trial Success: Viking Therapeutics' VK2735 achieved an average weight loss of up to 14.7% in just 13 weeks, outperforming other options on the market, showcasing its competitive edge in the weight-loss drug sector and potentially attracting more users.
- Analyst Optimism: Wall Street's consensus price target for Viking Therapeutics stands at $93.59, over 170% above its current price, reflecting analysts' strong optimism regarding upcoming clinical trial data and suggesting potential FDA approval.
- Differentiation Advantage: VK2735, as a dual agonist incorporating both GLP-1 and GIP therapies, offers a competitive edge with its tolerability and efficacy, which may help it stand out in a crowded market despite similarities in underlying mechanisms with other drugs.
See More
Amazon Launches GLP-1 Weight Management Program
- Service Launch: Amazon One Medical has announced a weight management program centered around GLP-1 treatments, aiming to address obesity as a chronic condition by integrating medical services to provide personalized solutions, thereby enhancing the overall healthcare experience for patients.
- Drug Accessibility: The program allows patients to order popular GLP-1 medications, including Foundayo and oral Wegovy, online at prices comparable to the market, while also offering 24/7 prescription renewals, significantly simplifying the weight loss journey for patients.
- Market Potential: With the surging demand for GLP-1 drugs, Amazon's weight management program is poised to attract a large number of patients, potentially driving revenue growth for Amazon One Medical through membership fees and medical services, thereby enhancing its competitiveness in the healthcare sector.
- Strategic Implications: Although Amazon's cloud computing business remains its primary profit driver, the weight management program could emerge as a significant growth engine for its healthcare services, further solidifying Amazon's position in the rapidly expanding GLP-1 market.
See More
Amazon Launches GLP-1 Weight Management Program
- Market Potential: The GLP-1 drug market is projected to approach $100 billion by 2030, with Eli Lilly and Novo Nordisk dominating the space and recently launching oral medications Foundayo and Wegovy, indicating strong market demand and competitive pressure.
- Amazon's Healthcare Strategy: Amazon is leveraging its One Medical platform to launch a GLP-1 weight management program that integrates virtual and in-person medical services, aiming to provide personalized weight loss solutions that cater to patients' needs for convenient healthcare, thereby enhancing its competitiveness in the healthcare sector.
- Convenient Access to Medications: Patients can easily order GLP-1 medications through Amazon One Medical, benefiting from fast delivery services, while existing patients enjoy 24/7 prescription renewals, which may attract more patients to choose Amazon as their preferred weight loss platform.
- Growth Drivers: Amazon's weight management program is expected to drive growth for One Medical through membership fees and medical service revenues; although GLP-1 drugs may not become a major growth engine for Amazon's overall business, they could represent a significant revenue source within its healthcare services ecosystem.
See More
Avaí Bio Advances Anti-Aging Therapeutics Development
- Market Growth Potential: The global anti-aging market surpassed $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science doubling to $8.49 billion last year, indicating strong growth potential in this sector.
- FDA Drug Approvals: The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025, including the first drug class termed 'longevity therapeutics', highlighting a rapid transformation in the biopharmaceutical industry that is driving market demand.
- Avaí Bio's Strategic Shift: Avaí Bio completed its rebranding in February 2026, focusing on developing cellular therapies for diabetes and age-related diseases, leveraging genetically engineered cells and protective encapsulation technology to accelerate progress towards functional cures.
- Aging Population Drives Demand: Adults aged 60 and older represent 17% of the U.S. population but account for 37% of healthcare spending, with the global 60+ population expected to reach 1.4 billion by 2030, underscoring the urgent need for anti-aging treatments.
See More
Avaí Bio Advances Longevity Therapeutics Development
- Market Growth Potential: The global anti-aging market surpassed $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science doubling to $8.49 billion last year, indicating strong growth potential in the sector.
- FDA Drug Approvals: The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025, including GLP-1 receptor agonists, recognized as the first class of 'longevity therapeutics,' marking significant advancements in the biopharmaceutical industry.
- Avaí Bio's Strategic Shift: Avaí Bio completed its rebranding in February 2026, focusing on developing cellular therapies for diabetes and age-related diseases, leveraging genetically engineered cell lines and protective encapsulation technologies to accelerate progress toward functional cures.
- Aging Population Drives Demand: Adults aged 60 and older represent 17% of the U.S. population but account for 37% of healthcare spending, with the global 60+ population expected to reach 1.4 billion by 2030, highlighting strong market demand for anti-aging therapies.
See More
Viking Therapeutics' Bullish Outlook with Target Price Raised Significantly
- Target Price Surge: Analysts project Viking Therapeutics' stock to reach $93.59 within the next 12 months, representing a more than 170% increase from its current price, indicating strong market confidence in its weight-loss drug VK2735.
- Clinical Trial Success: VK2735 achieved an average weight loss of up to 14.7% in just 13 weeks, outperforming other market options, with most users able to adhere to the treatment regimen, providing a significant competitive edge in the crowded weight-loss drug market.
- Massive Market Potential: The anti-obesity drug market is expected to grow from $26 billion last year to over $130 billion by 2031, positioning Viking Therapeutics to capture a share of this rapidly expanding market with its unique dual agonist VK2735.
- Analyst Optimism: Despite inherent risks, analysts remain bullish on Viking Therapeutics, anticipating that upcoming Phase 3 trial data will lead to FDA approval by no later than 2029, suggesting a strong buy sentiment among the majority of analysts covering the stock.
See More
Viking Therapeutics Poised for Growth in Weight-Loss Drug Market
- Market Potential: According to Mordor Intelligence, the anti-obesity drug market is projected to grow from $26 billion last year to over $130 billion by 2031, indicating strong growth potential, with Viking Therapeutics well-positioned in this space.
- Clinical Trial Success: Viking Therapeutics' VK2735 achieved an average weight loss of up to 14.7% in just 13 weeks, outperforming other options on the market, showcasing its competitive edge in the weight-loss drug sector and potentially attracting more users.
- Analyst Optimism: Wall Street's consensus price target for Viking Therapeutics stands at $93.59, over 170% above its current price, reflecting analysts' strong optimism regarding upcoming clinical trial data and suggesting potential FDA approval.
- Differentiation Advantage: VK2735, as a dual agonist incorporating both GLP-1 and GIP therapies, offers a competitive edge with its tolerability and efficacy, which may help it stand out in a crowded market despite similarities in underlying mechanisms with other drugs.
See More
Amazon Launches GLP-1 Weight Management Program
- Service Launch: Amazon One Medical has announced a weight management program centered around GLP-1 treatments, aiming to address obesity as a chronic condition by integrating medical services to provide personalized solutions, thereby enhancing the overall healthcare experience for patients.
- Drug Accessibility: The program allows patients to order popular GLP-1 medications, including Foundayo and oral Wegovy, online at prices comparable to the market, while also offering 24/7 prescription renewals, significantly simplifying the weight loss journey for patients.
- Market Potential: With the surging demand for GLP-1 drugs, Amazon's weight management program is poised to attract a large number of patients, potentially driving revenue growth for Amazon One Medical through membership fees and medical services, thereby enhancing its competitiveness in the healthcare sector.
- Strategic Implications: Although Amazon's cloud computing business remains its primary profit driver, the weight management program could emerge as a significant growth engine for its healthcare services, further solidifying Amazon's position in the rapidly expanding GLP-1 market.
See More
Amazon Launches GLP-1 Weight Management Program
- Market Potential: The GLP-1 drug market is projected to approach $100 billion by 2030, with Eli Lilly and Novo Nordisk dominating the space and recently launching oral medications Foundayo and Wegovy, indicating strong market demand and competitive pressure.
- Amazon's Healthcare Strategy: Amazon is leveraging its One Medical platform to launch a GLP-1 weight management program that integrates virtual and in-person medical services, aiming to provide personalized weight loss solutions that cater to patients' needs for convenient healthcare, thereby enhancing its competitiveness in the healthcare sector.
- Convenient Access to Medications: Patients can easily order GLP-1 medications through Amazon One Medical, benefiting from fast delivery services, while existing patients enjoy 24/7 prescription renewals, which may attract more patients to choose Amazon as their preferred weight loss platform.
- Growth Drivers: Amazon's weight management program is expected to drive growth for One Medical through membership fees and medical service revenues; although GLP-1 drugs may not become a major growth engine for Amazon's overall business, they could represent a significant revenue source within its healthcare services ecosystem.
See More
Avaí Bio Advances Anti-Aging Therapeutics Development
- Market Growth Potential: The global anti-aging market surpassed $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science doubling to $8.49 billion last year, indicating strong growth potential in this sector.
- FDA Drug Approvals: The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025, including the first drug class termed 'longevity therapeutics', highlighting a rapid transformation in the biopharmaceutical industry that is driving market demand.
- Avaí Bio's Strategic Shift: Avaí Bio completed its rebranding in February 2026, focusing on developing cellular therapies for diabetes and age-related diseases, leveraging genetically engineered cells and protective encapsulation technology to accelerate progress towards functional cures.
- Aging Population Drives Demand: Adults aged 60 and older represent 17% of the U.S. population but account for 37% of healthcare spending, with the global 60+ population expected to reach 1.4 billion by 2030, underscoring the urgent need for anti-aging treatments.
See More
Avaí Bio Advances Longevity Therapeutics Development
- Market Growth Potential: The global anti-aging market surpassed $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science doubling to $8.49 billion last year, indicating strong growth potential in the sector.
- FDA Drug Approvals: The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025, including GLP-1 receptor agonists, recognized as the first class of 'longevity therapeutics,' marking significant advancements in the biopharmaceutical industry.
- Avaí Bio's Strategic Shift: Avaí Bio completed its rebranding in February 2026, focusing on developing cellular therapies for diabetes and age-related diseases, leveraging genetically engineered cell lines and protective encapsulation technologies to accelerate progress toward functional cures.
- Aging Population Drives Demand: Adults aged 60 and older represent 17% of the U.S. population but account for 37% of healthcare spending, with the global 60+ population expected to reach 1.4 billion by 2030, highlighting strong market demand for anti-aging therapies.
See More
